11 research outputs found
Recommended from our members
Second Primary Cancer Risk of Radiation Therapy After Radical Prostatectomy for Prostate Cancer: An Analysis of SEER Data
To determine the incidence of second primary cancer (SPC) and primary pelvic late SPC/radiation-induced SPC after radical prostatectomy and radiation.
A total of 228 235 prostate cancer patients in the 1973-2002 Surveillance, Epidemiology, and End Results database were studied. The age-adjusted estimates of SPCs was calculated. Competing risk multivariable Cox proportional hazards regression analysis was adjusted for age at diagnosis, race or ethnicity, and radiation and was used to evaluate the effect of treatment on SPC.
The overall incidence of SPC was 8.4%. The most frequent pelvic SPCs were bladder (2303 cases), rectum or rectosigmoid junction (1006 cases). The most frequent nonpelvic SPCs were bronchus and lung (4131 cases), colon (2665 cases), and skin (1769 cases). The absolute risk of developing a second malignancy was 1747 cases per 100 000 in the “Radical surgery and x-ray treatment” group and 1581 in the “radical surgery” group. With regard to late primary pelvic SPC, a higher age-adjusted rate of 374 cases per 100 000 was seen in the radiated group.
Radiation after radical surgery increased late primary pelvic SPC. No increases were seen in secondary pelvic or extrapelvic SPCs
Recommended from our members
Phase II study of tolerance and efficacy of hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (taxol) and amifostine (ethyol) in head and neck squamous cell carcinomas: A-3 protocol
The objective of this study was to determine the toxicity and efficacy of the current phase II chemoradiation protocol. Stage III or IV locally advanced head and neck squamous cell carcinomas arising from the oral cavity, hypopharynx, oropharynx, nasopharynx, paranasal sinuses, or larynx were treated using hyperfractionated radiation (74.4 Gy at twice-daily fractions of 1.2 Gy) in combination with a 5-fluorouracil, cisplatin, paclitaxel regimen, and an amifostine infusion. Thirty-five of 36 eligible patients were evaluable. The overall survival (OVS) was 88%, 82%, and 66% at 1, 2, and 3 years respectively. Twenty-five patients (71%) had a complete response, which was maintained in 20 (57%) patients until last follow up or death. Disease-free survival (DFS) of the complete responders was 92% at 1 year and 77% at 2 years and 3 years, respectively. Percutaneous endoscopic gastrostomy dependency lasted for a median of 7 months. Grade 3 and 4 mucositis occurred in 23 and 3 patients, respectively. Comparison with a similar study (A-2) that did not include amifostine showed no significant benefit to the addition of amifostine in these patients. A locoregional control benefit should be confirmed in a prospective, randomized trial. Alternative amifostine delivery methods should be investigated